Morphic Therapeutic to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference

Morphic Therapeutic (Nasdaq: MORF) announced that its CEO, Praveen Tipirneni, M.D., will present at the virtual 40th Annual J.P.

Rhea-AI Summary

Morphic Therapeutic (Nasdaq: MORF) announced that its CEO, Praveen Tipirneni, M.D., will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 2:15 PM ET. The presentation will focus on the company's advancements in developing oral integrin therapies targeting chronic diseases. A live webcast can be accessed via the investor section of Morphic's website, with a replay available afterward. Morphic is collaborating with major firms to enhance its therapies using its proprietary MInT technology platform.

Argus Session date unavailable

-7.11% session move Open Argus

Details

News Market Reaction – MORF

The recorded move for MORF in the trading session of this news was -7.11%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., President and Chief Executive Officer, will present at the virtual 40^th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 2:15 PM ET.

A live webcast of the presentation will be available on the Investor section of Morphic’s website at www.morphictx.com. An archived replay will be available on the company’s website following the conference.

About Morphic Therapeutic
Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen, and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.

Contacts
Morphic Therapeutic
Chris Erdman
chris.erdman@morphictx.com
617.686.1718

Media Contact
Tom Donovan, Ten Bridge Communications
tom@tenbridgecommunications.com
857.559.3397

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Morphic Therapeutic present at the J.P. Morgan Healthcare Conference?

Morphic Therapeutic will present at the J.P. Morgan Healthcare Conference on January 12, 2022, at 2:15 PM ET.

Where can I watch the Morphic Therapeutic presentation?

The presentation can be watched live on the investor section of Morphic Therapeutic's website.

What is the focus of Morphic Therapeutic's presentation at the conference?

The focus will be on Morphic's developments in oral integrin therapies for chronic diseases.

What technology does Morphic Therapeutic use for its therapies?

Morphic Therapeutic uses its proprietary MInT technology platform to advance its therapies.

Who is the CEO of Morphic Therapeutic?

The CEO of Morphic Therapeutic is Praveen Tipirneni, M.D.